Labelled StealthR liposomes in experimental infection : an alternative to leukocyte scintigraphy? by Oyen, W.J.G. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
This full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/15095
 
 
 
Please be advised that this information was generated on 2014-11-11 and may be subject to
change.
Nuclear Medicine Communications, 1996, 17, 742-748 N u c l e a rMedicine
Communications
Labelled StealthK liposomes in experimental 
infection: An alternative to leukocyte 
scintigraphy?
W.J.G. OYEN,1* O.C. BOERMAN,1 G. STORM,3 L. VAN BLOOIS,3 
E.B. KOENDERS,1 D.J.A. CROMMELIN,3 J.W.M. VAN DER MEER2 
and F.H.M. CORSTENS1
Departments of Nuclear Medicine and 2Internal Medicine, University Hospital Nijmegen, Nijmegen and 
departm ent of Pharmaceutics, Institute for Pharmaceutical Science, Utrecht University, Utrecht, The 
Netherlands
Received 10 March 1996 and accepted 18 March 1996
Summary
Indium-111 (lnIn) and technetium-99m ("Tcm) StealthR liposomes were compared with niIn- and "Tcm- 
labelled white blood cells (WBC) in experimental infection in a rabbit model. Preformed polyethylene 
glycol-coated liposomes and separated WBC were radiolabelled with either mIn-oxine or "Tcm-hexame- 
thylpropyleneamine oxime (99Tcm-HMPAO). After the intravenous administration of one of the four 
radiopharmaceuticals to rabbits with focal Staphylococcus aureus infection, scintigraphic images were 
recorded at various time points post-injection and the biodistribution of the radiopharmaceuticals was 
determined. At 4 h post-injection, uptake of nlIn-WBC in the abscess was significandy higher than that 
of the three other products. At later time points, mIn-WBC, lllIn-liposome and MTcm-liposome uptake in 
the abscess were similar. In contrast, at 20 h post-injection, uptake of "Tcm-WBC was significantly lower. 
The abscess-to-background ratios showed a similar pattern to the absolute abscess uptake: initial high 
values for ulIn-WBC, a more gradual increase over time of the liposome preparations to the level of mIn- 
WBC and persistently low values for "Tcm-WBC. Clearance from the blood of both labelled WBC pre­
parations was significantly faster and splenic uptake significantly higher compared with those of the 
labelled liposomes. In conclusion, given the similar in vivo characteristics of labelled liposomes 
and labelled WBC, labelled liposomes may be an attractive replacement for labelled WBC, providing a 
continuously available, high-quality, "Tcm-labelled radiopharmaceutical that can be prepared easily 
without any need to handle blood.
Introduction
Scintigraphic delineation of focal infection is a clinically 
important procedure, not only to identify infectious and 
inflammatory foci, but also to evaluate their activity [1]. 
Despite the development of new agents, autologous leu­
kocyte (WBC) scintigraphy, using either indium-111 
(in In) or technetium-99m (99Tcm), is still the imaging 
procedure of choice in routine clinical practice [2]. 
Unfortunately, the preparation of radiolabelled auto­
logous leukocytes has several disadvantages which limit
‘Address all correspondence to Wim J.G. Oyen, D epartm ent of Nuclear 
Medicine, University H ospital Nijmegen, PO Box 9101, 6500 HB Nij­
megen, The Netherlands.
its application. In particular, the need to withdraw and 
handle blood that may be infected constitutes an inher­
ent risk to other patients and staff [3, 4]. Moreover, the 
isolation and labelling of leukocytes is a relatively 
complicated and time-consuming procedure that is not 
possible in every laboratory. One approach to facilitate 
infection imaging is the application of labelled proteins 
and peptides [5-7]. These radiopharmaceuticals accumu­
late in infection by specific receptor or antigen inter­
action or non-specific deposition [7]. Another method to 
prevent the handling of blood is the use of StealthR lipo­
somes. These are phospholipid bilayers with a poly­
ethylene coating that prevent rapid uptake of circulating 
particles by the mononuclear phagocytic system [8].
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These liposomes are radiolabelled analogously to leuko­
cytes either with U1ln or "Tcm [9, 10]. In initial animal 
studies, a number of characteristics of labelled liposomes 
resembled those of labelled leukocytes in hum ans in 
terms of biodistribution and the ability to detect various 
infections [10]. In this study, the in vivo  characteristics of 
labelled StealthR liposomes are compared w ith those 
of labelled leukocytes, both labelled with either in In or 
"Tcm in a rabbit model of mild focal Staphylococcus 
aureus infection.
Materials and m ethods
Animal model
A calf muscle abscess was induced in female, random ly 
bred New Zealand white rabbits (body weight 2.5-3.0 
kg). Approximately 109 colony forming units (CFU) of S. 
aureus in 0.5 ml of a 50:50% suspension of autologous 
blood and normal saline was injected into the left calf 
muscle [11], Twenty-four hours after the inoculation, 
when swelling of the muscle was apparent, the respec­
tive radiopharmaceuticals were injected via the ear 
vein.
Preparation of liposomes
Partially hydrogenated egg-phosphatidylcholine with an 
iodine value of 40 (PHEPC) was obtained from Asahi 
Chemical Industry Co., Ltd (Ibarakiken, Japan) [12]. The 
polyethylene glycol (PEG) 1900 derivative of distearoyl- 
phosphatidyl-ethanolamine (PEG-DSPE) was a kind gift 
from Liposome Technology, Inc. (Menlo Park, CA) and 
prepared as described previously [13]. The cholesterol 
was obtained from Sigma Chemical Co. (St. Louis, MO) 
and the glutathione from E. Merck (Darmstadt, Ger­
many). A chloroform/methanol mixture (10/1, v /v ) 
containing PEG-DSPE, PHEPC and cholesterol was pre­
pared in a molar ratio of 0.15:1.85:1. A lipid film was 
formed by rotary evaporation followed by high vacuum 
to remove residual organic solvent [14].
For encapsulation of glutathione (for subsequent 9yTcm 
labelling), the film was hydrated at room temperature 
with 50 mM glutathione in HEPES buffer (10 mM HEPES, 
135 mM NaCl, pH 7.4) at an initial phospholipid concen­
tration of 120 m M . For encapsulation of Desferal (for 
subsequent u lIn labelling), the lipids were dispersed at 
room temperature in 6 mM Desferal in 0.9% HEPES 
buffer (10 mM HEPES, 135 mM NaCl, pH 7.5) at an initial 
phospholipid concentration of 120 m M . The liposomes 
were sequentially extruded through polycarbonate fil­
ters of 0.6, 0.2, 0.1 and 0.08 pm pore size (Poretics, Liver­
more, CA, USA). Unentrapped glutathione or Desferal 
was removed by gel filtration on an EconoPac 10DG col­
umn (Bio-Rad, Richmond, CA, USA). The particle size 
distribution was determined by dynamic light scattering
with a Malvern 4700 system using a 25 mW He-Ne laser 
and the automeasure 3.2 software (Malvern, UK). As a 
measure of particle size distribution of the dispersion, a 
polydispersity index was determined, ranging from 0.0 
(entirely monodisperse) to 1.0 (completely polydisperse). 
The mean size of the liposome dispersions was 120 nm, 
with a polydispersity index of 0.2.
Radiolabelling of liposomes
Preformed glutathione-containing liposomes were 
labelled by transporting "Tcm as a lipophilic "Tcm- 
hexamethylpropyleneamine oxime (99Tcm-HMPAO) 
complex through the bilayer. The "Tcm-HMPAO is sub­
sequently irreversibly trapped in the internal aqueous 
phase due to reduction by the encapsulated glutathione 
[15]. One milligram of "Tcm-HMPAO was incubated 
with 2.5 GBq "T cm-pertechnetate. The liposomes were 
incubated for 15 min at room temperature w ith 1 MBq 
"Tcm-HMPAO per pmol phospholipid. Removal of 
unencapsulated "Tcm-HMPAO was achieved by gel 
filtration on a EconoPac 10DG column (Bio-Rad, Rich­
mond, CA) with 5% glucose as the eluent. Thus, a radio­
chemical purity -  as checked by a second column elution 
-  of more than 98% was achieved. Altogether, 200 MBq 
"Tcm-liposomes were injected intravenously.
Preformed Desferal-containing liposomes were 
labelled with m In, essentially as described previously 
[16, 17]. in In was transported in the form of 111In-oxine 
through the bilayer and trapped irreversibly in the inter­
nal aqueous phase by the encapsulated Desferal. Briefly, 
the liposomes (75 pm ol phospholipid per ml) were incu­
bated for 1 h at room temperature with 75-100 kBq m In- 
oxine (Mallinckrodt Medical, Petten, The Netherlands) 
per pmol phospholipid. Removal of unencapsulated 
lu In-oxine was achieved by gel filtration on an Econo­
Pac 10DG column (Bio-Rad, Richmond, CA). A  radio­
chemical purity of more than 98% was achieved. Twenty 
MBq 111 In-liposomes were injected intravenously.
Preparation and radiolabelling of leukocytes
For each labelling, 100 ml of blood was w ithdraw n care­
fully from an anaesthetized donor rabbit by carotid 
artery cannulation into 60 ml syringes, each containing 
10 ml 0.33% methylcellulose in acid citrate dextrose 
(ACD). The total white blood cell count of the donor 
rabbits was 8.5 x 109 I -1 ("Tcm labelling) and 1 2 x l0 9 
I -1 (n lIn labelling) with approximately 50% granulo­
cytes. The erythrocytes were allowed to sediment for 1 h. 
The supernatant was removed and centrifuged for 10 
min at 450 g. The cell pellet was washed with 5 m l phos­
phate buffered saline (PBS) (pH =  7.4), 1% HSA and 
centrifuged once more for 10 min at 450 g. The cell pellet 
was resuspended in 1.5 ml in PBS, 1% HSA. Then, 2 GBq
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"Tcm-HMPAO or 100 MBq M1In-oxine solution (Mal- 
linckrodt Medical, Petten, The Netherlands) in 0.2 m  Tris- 
hydroxymethyl-aminomethane (pH = 8.0) was added 
to the cell suspension. The cells were incubated at room 
temperature for 30 min and centrifuged for 10 min at 450 
g. The cell pellet was resuspended in 5 ml PBS, 1% HSA 
(niIn-WBC) or 5% glucose (99Tcm-WBC). Morphological 
integrity of the WBC was checked by light microscopy 
examination. The labelling efficiency (cell associated 
activity/total activity) was higher than 95% for m In- 
WBC and 75% for "Tcm-WBC. Twenty MBq irlIn-WBC 
or 200 MBq "Tcm-WBC were administered intrave­
nously.
Study design
Twenty-four hours after S. aureus infection, groups of 
four rabbits each were injected via the ear vein with 
either "Tcm-liposomes, "Tcm-WBC, 111 In-liposomes or 
m In-WBC. The rabbits were immobilized and placed 
prone on a single-head gamma camera equipped with a 
parallel-hole, low-energy (9yTcm studies) or medium- 
energy (m In studies) collimator (Siemens Orbiter, Sie­
mens Inc., Hoffmann Estate, IL). Each rabbit was imaged 
at 5 min, 1 h, 4 h, 8 h, 20 h and 48 h (in In only) after
injection. Images (100,000 counts per rabbit) were 
obtained and stored in a 256 x 256 matrix.
The scintigrams were analysed by drawing regions of 
interest over the abscess, over the non-infected contra­
lateral calf muscle (used as a background region), over 
the heart (representing blood pool activity), the lung 
(labelled leukocytes) and over the whole animal. Whole- 
body retention, blood clearance, lung clearance, abscess- 
to-background ratios and percentage activity remaining 
in the abscess (abscess-to-whole body ratio) were cal­
culated.
After acquiring the final images, the rabbits were sac­
rificed with an overdose of sodium phenobarbital and 
biodistribution was determined. Blood was obtained by 
cardiac puncture. Tissues (infected left calf muscle, right 
calf muscle, liver, spleen, kidney, duodenum, right 
femur and bone marrow from the right femur) were dis­
sected, weighed and their activity was measured in a 
shielded well-type gamma counter. To correct for physi­
cal decay and to permit calculation of the uptake of the 
radiopharmaceuticals in each organ as a fraction of 
the injected dose, aliquots of the injected dose were 
counted simultaneously The results were expressed as
Fig. 1. (A) 111 In-WBC and (B) 
lnIn-liposomes 48 h post-injec­
tion; (C) 9‘JTcm-WBC and (D) 
1J9Tcm-liposomes 20 h post­
injection. In all images, the S. 
aureus abscess can be clearly 
seen (arrow). For all four radio­
pharmaceuticals, spleen (WBC 
> liposomes), liver and bone 
marrow uptake can be visual­
ized. The "Tcm-labelled pre­
parations show renal uptake 
and both liposome products 
residual blood pool activity 
(heart). Gut activity is only 
apparent after injection of 
"Tcm-WBC.
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percent injected dose per gram (%ID g -1)- Abscess-to- 
muscle, abscess-to-blood and abscess-to-bone marrow 
ratios were calculated.
Statistical analysis
All mean values are given as %ID g ~1 or ratios ±  one 
standard error of the mean ( s . e . m . ) .  Statistical analysis 
was performed using one-way analysis of variance 
(ANOVA). The level of significance was set at 
P  <  0.05.
Comparison of labelled liposomes and leukocytes
Results
Figure 1 shows images recorded at 48 h (n iIn label) and 
20 h ("Tcm label) post-injection. The abscess can be 
clearly seen with all four radiopharmaceuticals. Quanti­
tative analysis of the scintigraphic data revealed very 
similar whole-body retention over time of 111 In-WBC 
and 111 In-liposomes (Fig. 2A). The "Tcm preparations 
cleared significantly faster from the body than the m In- 
labelled preparations (after 1 h post-injection, P  <  0.05).
hours  post in jec tion
hours post in jection
From 8 h post-injection onwards, the whole-body reten­
tion of "Tcm-WBC was significantly lower than that of 
"Tcm-liposomes. In contrast, blood clearance of both 
liposome form ulations was significantly slower than the 
blood clearance of labelled WBC (P  <  0.001 at 1 h 
post-injection and all later time points; see Fig. 2B). 
There was no difference between li:In- and "T cm-lipo- 
some blood clearance, nor between rn In- and "Tcm- 
WBC blood clearance. W hile both liposome formulations 
showed low pulm onary activity, both n iIn- and "Tcm- 
labelled WBC show ed initial m argination in the lungs 
(image not shown). As shown in Fig. 2C, after the initial 
entrapment in  the lungs, fast clearance of the labelled 
cells from the lungs into the circulation was observed 
with a first half-life of less than 1 h. From 4 h post­
injection onwards, the relative pulm onary uptake of 
"Tcm-WBC was significantly lower than that of in In- 
WBC (P < 0.05).
Figure 3A shows abscess uptake over time as deter­
mined scintigraphically. At 4 h  post-injection, uptake of 
111 In-WBC was significantly higher than that of the other 
three radiopharm aceuticals (P <  0.05). At later time
745
hours  pos t in jec tio n
Fig. 2. Whole-body retention (A), blood clearance (B) and lung 
clearance (C). The value obtained at 5 min post-injection was 
set at 100%.
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points, uptake of luIn-WBC, ^In-liposome and "Tcm- 
liposome in the abscess was similar. In contrast, at 20 h 
post-injection, uptake of "Tcm-WBC was significantly 
lower than the uptake of the other three radiopharma­
ceuticals (P < 0.05). The abscess-to-background ratios 
(Fig. 3B) and the remaining activity in the abscess (Fig. 
3C) showed a similar pattern to the absolute abscess 
uptake: initial high values for n iIn-WBC, a more gradual 
increase over time of the liposome preparations to the 
level of niIn-WBC and persistently low values for "Tcm- 
WBC (P <  0.05).
The biodistribution data (see Table 1) confirmed the 
scintigraphic data obtained at 48 h (m In-labelled pre­
parations) and 20 h ("Tcm-labelled preparations) post­
injection. Abscess uptake and abscess-to-muscle ratios 
were high for both m In-WBC and m In-liposomes. 
Abscess uptake of "Tcm-liposomes was higher than that 
of 99Tcm_WBC (0.11 ±0.01 vs 0.03 + 0.003 %1D g “ 1; 
P <  0.01), as were the abscess-to-muscle (P <  0.05) and 
abscess-to-bone marrow ratios (P <  0.05). The low 
blood levels of "Tcm-WBC resulted (despite lower
abscess uptake) in relatively high abscess-to-blood ratios 
compared with "Tcm-liposomes (P <  0.01). Both the 
ln In- and the "Tcm-labelled liposomes showed higher 
blood levels than the m In- and "Tcm-WBC (P < 0.01 
and P < 0.001, respectively). m In-WBC and in In-lipo- 
some uptake was very similar in all organs except the > 
spleen, where it was markedly higher for m In-WBC 
(3.25 ±0.12 vs 0.70 ±0.07 %ID g _1; P <  0.001). 
Although less striking than for the m In-labelled prod­
ucts, splenic uptake of "Tcm-WBC was higher than that 
of "Tcm-liposomes (0.66 ± 0.14 vs 0.35 ± 0.07 %ID g -1; 
P <  0.05). Lung and duodenal uptake of "Tcm-lipo- 
somes were higher than those of "Tcm-WBC 
(P < 0.01).
Discussion
StealthR liposomes labelled with either 111In or "Tcm 
depicted focal abscess as well as ^In-labelled leuko­
cytes. Abscess accumulation of niIn-WBC was initially 
fast and high compared with both liposome formula­
tions. However, by 4 h post-injection this difference had
A
hours post Injection hours post injection
hours post injection Fig. 3. Abscess uptake (A), abscess-to-background ratio (B) 
and remaining activity in the abscess (C).
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Table 1. Mean ( ± s . d . )  biodistribution data (%ID g ') and ratios for ln In-labelled leukocytes and StealthR liposomes (48 h post­
injection) and for "Tcm-labelled leukocytes and StealthR liposomes (20 h post-injection).
m In-WBC m  In-liiposomes 99Tc'"-WBC "Tc"'-liposomes
Abscess 0.14 ± 0.04 — 0.16 ± 0.02 0.03 ± 0.003 ** 0.11 ± 0.01
Muscle 0.005 ± 0.001 — 0.008 ± 0.001 0.002 ± 0.001 -- 0.003 ± 0.001
Blood 0.18 ± 0.01 ** 0.31 ± 0.03 0.04 ± 0.005 *** 0.27 ± 0.01
Lung 0.10 ± 0.02 — 0.11 ± 0.03 0.04 ± 0.001 ** 0.08 ± 0.005
Spleen 3.25 ± 0.12 *** 0.70 ± 0.07 0.66 ± 0.14 *• 0.35 ± 0.07
Liver 0.24 ± 0.02 — 0.20 ± 0.03 0.10 ± 0.02 -- 0.13 ±0.01
Kidney 0.15 ± 0.01 — 0.11 ± 0.01 0.13 ± 0.02 -- 0.15 ±0.01
Duodenum 0.02 ± 0.005 — 0.04 ± 0.01 0.01 ± 0.001 ** 0.04 ± 0.005
Bone marrow 0.34 ± 0.02 — 0.36 ± 0.07 0.18 ± 0.03 -- 0.19 ± 0.02
Femur 0.02 ± 0.005 — 0.02 ± 0.005 0.007 ± 0.001 -- 0.01 ± 0.002
Abscess-to-muscle ratio 29.9 ± 9.8 _ 20.9 ± 3.3 24.2 ± 2.7 * 38.6 ± 6.7
Abscess-to-blood ratio 0.8 ± 0.3 — 0.5 ± 0.1 0.8 ± 0.1 ** 0.4 ± 0.1
Abscess-to-bone marrow 
ratio 0.4 ±0.1 — 0.5 ±0.1 0.2 ± 0.1 * 0.6 ±0.1
— Not significant; * P <  0.05; ** P <  0.01; *** P <  0.001.
disappeared. The StealthR liposomes labelled w ith either 
"Tcm or in In showed similar abscess uptake on scinti­
graphy. In previous studies using a rat model of infec­
tion, absolute abscess uptake of liposomes appeared to 
be higher than in the present study [9,10]. However, the 
present study was not only performed in a different spe­
cies, but also the inflammatory response was much 
lower in the rabbits employed. We were forced to use 
relatively low S. aureus doses (approximately 4 x 10s 
CFU per kg body weight in rabbits vs  5 x 109 CFU per kg 
body weight in rats), since a higher bacterial load causes 
sepsis and subsequent mortality. In contrast to the other 
three formulations, "Tcm-WBC showed relatively low 
abscess uptake. This could not be explained by the poor 
quality of the radiopharmaceutical, since (for both m In- 
WBC and 99Tcm-WBC) the leukocytes were morpholog­
ically intact and the two in vivo quality requirements 
were met: fast pulmonary transit and low liver uptake 
[18],
With regard to the kinetics of the radiopharm aceut­
icals, both the label and the pharmaceutical formulation 
(cell or liposome) played an important role. Whole-body 
retention was mainly determined by the radiolabel and 
the labelling method. In contrast to the m In formula­
tions, which were totally retained in the body, the "Tcm- 
labelled agents showed considerable excretion. There 
was significantly less "Tcm excretion when labelled lipo­
somes (10% ID over 20 h) were used compared with 
"Tcm-WBC (30% ID over 20 h). This could be explained 
by the purification procedure of the "Tcm-liposomes; 
which removes the majority of unbound "Tcm-HMPAO 
(resulting in more than 95% radiochemical purity of the 
99Tcm-liposomes). "Tcm-WBC can only be purified by
repeated w ashing of the cell suspension w ith 5% glucose 
solution, while gel filtration is impossible. In contrast to 
whole-body retention, blood clearance of the radiophar­
maceuticals w as determined by the pharmaceutical for­
mulation: both leukocyte preparations cleared 
significantly faster than the labelled liposomes, resulting 
in relatively low er background activity of the labelled 
leukocytes, especially at the earlier time points.
The m ost striking difference in biodistribution 
between leukocytes and liposomes was the relatively 
low splenic uptake of the latter. In hum ans, this would 
not only im prove image quality in the upper abdomen, 
but w ould also reduce the radiation burden to the spleen 
and long-living T-lymphocytes, especially when using 
m In [19]. In liver, kidney and-bone marrow, uptake of 
the labelled WBC and liposomes was similar. For the 
"Tcm preparations, lung uptake of liposomes was higher 
than that of leukocytes. This was m ost probably related 
to the higher blood level of "Tcm-liposomes. This may 
also have been the case for duodenal wall activity, espe­
cially since the "T cm~liposome images revealed a much 
clearer picture of the abdomen than the "Tcm-WBC 
images. Similar to the lower renal excretion rate of "Tcm- 
liposomes com pared with "Tcm-WBC, the lower intesti­
nal activity could again be explained by the extra 
purification required to remove non-liposomal "Tcm- 
HMPAO.
When com paring the labelled StealthR liposomes with 
non-PEGylated liposomes, liver and splenic uptake was 
m uch lower than that of non-PEGylated larger lipo­
somes [20, 21]. Also, bone m arrow uptake is lower for 
StealthR liposomes. Blood clearance and uptake of 
StealthR and non-PEGylated 99Tcm-labelled liposomes in
Nuclear Medicine Communications (1996) 17
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other organs are similar [20]. Whole-body excretion of 
.radioactivity is also similar for both formulations. Over­
all, targeting of the infectious focus with "T cm-StealthR 
liposomes is at least as good as, or even better than, that 
of "Tcm-non-PEGylated liposomes [10, 20].
Given the similar in vivo characteristics of labelled 
liposomes and labelled leukocytes, the advantage of the 
liposome formulation would be the continuous avail­
ability of a high-quality, "Tcm-labelled radiopharma­
ceutical that can be prepared easily from a lyophilized 
kit without the need to handle blood. In patient care, 
"Tcm-labelled liposomes would provide an attractive 
alternative to the laborious method of labelled leuko­
cytes, especially in acute infectious disease.
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